Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0002072045-25-000002
Filing Date
2025-06-12
Accepted
2025-06-12 18:15:12
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 6688
2 CONSULTING AGREEMENT WITH QUANTUM BIOPHARMA INC. Ex99_1_QNTM_Advisory.pdf EX-99.1 CHARTER 99639
  Complete submission text file 0002072045-25-000002.txt   145979
Mailing Address FIRST CANADIAN PLACE 100 KING STREET WEST, SUITE 4000 TORONTO A6 M5X 1A4
Business Address FIRST CANADIAN PLACE 100 KING STREET WEST, SUITE 4000 TORONTO A6 M5X 1A4 (416) 854-8884
Quantum Biopharma Ltd. (Subject) CIK: 0001771885 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91661 | Film No.: 251044148
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 9201 W STATE ST. STE 126 BOISE ID 83714
Business Address 9201 W STATE ST. STE 126 BOISE ID 83714 2089854526
Malone Wealth Ventures LLC (Filed by) CIK: 0002072045 (see all company filings)

EIN.: 861544286 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13D